• 提示：詳情請下載說明書。

• 產(chǎn)品描述： STAT5-IN-1 是一種有效的選擇性 STAT5 抑制劑，其對于STAT5β亞型的IC50值為47 μM

• 靶點(diǎn)： STAT5β(Cell-free assay):47 μM;STAT

• 體外研究：
  STAT5-IN-1, the STAT5 phosphorylation specific inhibitor, selectively blocks the STAT5 signaling and decreases the percentage of CD4+CD25+Foxp3+ Tregs after SEC2 stimulation on murine splenocytes

• 體內(nèi)研究：
  STAT5-IN-1, a STAT5 inhibitor, significantly attenuates atherosclerosis in ApoE-/- mice induced by HFD via decreasing inflammation.

• 細(xì)胞實(shí)驗(yàn)： Cell lines: murine splenocytes Concentrations: 0.47 mM Incubation Time: 3 days Method: Fresh murine splenocytes seeded in 24-well flat-bottom plates are treated with each inhibitor at final concentrations of 10 μM LY294002, 10 mM Trigonelline, 0.47 mM STAT5-IN-1, 50 μM SB431542, and 1 μM SIS3, or treated with 10 μg/mL anti-IL-2 neutralizing antibody, respectively, then cells are stimulated with 104 ng/mL SEC2 for 3 days in a humidified incubator at 37 ℃ with 5% CO2.

• 動物實(shí)驗(yàn)： Animal Models: ApoE-/- mice Dosages: 10 mg/kg Administration: p.o.

• 參考文獻(xiàn)：
  1. Müller J, et al. Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem. 2008 Mar 25;9(5):723-7. 2. Li Y, et al. Induction of CD4+ regulatory T cells by stimulation with Staphylococcal Enterotoxin C2 through different signaling pathways. Biomed Pharmacother. 2021 Nov;143:112204. 3. Wang X, et al. STAT5 inhibitor attenuates atherosclerosis via inhibition of inflammation: the role of STAT5 in atherosclerosis. Am J Transl Res. 2021;13(3):1422-1431.

• 溶解性： Soluble  in  DMSO

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	3.41 ml	17.049 ml	34.097 ml
  5 mM	0.682 ml	3.41 ml	6.819 ml
  10 mM	0.341 ml	1.705 ml	3.41 ml
  50 mM	0.068 ml	0.341 ml	0.682 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

輸入產(chǎn)品批號：

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *